An updated network meta-analysis found that a triplet regimen consisting of lenalidomide and dexamethasone plus an immunotherapeutic agent had better efficacy in terms of NRR, TTP, PFS, and OS than other regimens.
The manufacturer of daratumumab, a CD38-directed antibody for the treatment of multiple myeloma, has submitted a sBLA and a type II variation to the US FDA and European Medicines Agency, respectively, for approval of a split dosing regimen.
Although the effectiveness and safety of bortezomib-based therapy for patients with R/R MM has been demonstrated in phase 2 and phase 3 clinical trials, data collected from real-world settings appear to confirm prior study results.
In an analysis of 11 studies, researchers investigated whether the benefits of carfilzomib for multiple myeloma outweigh the cardiovascular risks. However, the researchers recommend careful monitoring and management of blood pressure and volume status as good clinical practice, regardless.
Repeat primary care consultations before a diagnosis was assigned and non-specific symptoms were two factors that caused delays in the diagnosis of patients with myeloma following the appearance of symptoms.
In a single-arm phase 2 study, researchers explored the effectiveness of a modified lenalidomide, bortezomib, and dexamethasone (RVD-lite) regimen in transplant-ineligible patients with multiple myeloma.
A case series demonstrates the prevalence of MGUS, a precursor condition to multiple myeloma, and subsequent development of MM in white firefighters who responded after the 9/11 attacks in New York City.
In a post-hoc analysis of the ASPIRE trial results, in which carfilzomib was discontinued due to a lack of long-term safety data, researchers present the safety and efficacy findings of KRd vs Rd for relapsed multiple myeloma at 18 months from randomization.
A health outcomes analysis of 419 patients with multiple myeloma sought to determine if cipro-doxy was more effective than cipro alone in reducing the incidence of neutropenic fever and infections, both significant causes of morbidity and death for these patients.
Patients with quad- or penta-refractory myeloma have limited treatment options. Selinexor, an orally administered selective inhibitor of exportin 1 (XPO1), previously showed anti-myeloma activity in a phase 1 trial.